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Background: The epidermal growth factor receptor (EGFR) signaling pathway and angiogenesis in brain cancer act
as an engine for tumor initiation, expansion and response to therapy. Since the existing literature does not have
any models that investigate the impact of both angiogenesis and molecular signaling pathways on treatment, we
propose a novel multi-scale, agent-based computational model that includes both angiogenesis and EGFR modules
to study the response of brain cancer under tyrosine kinase inhibitors (TKIs) treatment.
Results: The novel angiogenesis module integrated into the agent-based tumor model is based on a set of
reaction–diffusion equations that describe the spatio-temporal evolution of the distributions of
micro-environmental factors such as glucose, oxygen, TGFα, VEGF and fibronectin. These molecular species regulate
tumor growth during angiogenesis. Each tumor cell is equipped with an EGFR signaling pathway linked to a
cell-cycle pathway to determine its phenotype. EGFR TKIs are delivered through the blood vessels of tumor
microvasculature and the response to treatment is studied.
Conclusions: Our simulations demonstrated that entire tumor growth profile is a collective behaviour of cells
regulated by the EGFR signaling pathway and the cell cycle. We also found that angiogenesis has a dual effect
under TKI treatment: on one hand, through neo-vasculature TKIs are delivered to decrease tumor invasion; on the
other hand, the neo-vasculature can transport glucose and oxygen to tumor cells to maintain their metabolism,
which results in an increase of cell survival rate in the late simulation stages.
Keywords: Multi-scale, Agent-based modeling, EGFR signaling pathway, Angiogenesis, TKI treatmentBackground
Brain cancer is a very complex and deadly disease. Trad-
itional diagnoses and treatments of this disease are from
in vitro experimental observations. Although biologists
have developed many experimental data at the molecu-
lar, cellular, micro-environmental and tissue scales, only
very few scientists have integrated these data into multi-
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reproduction in any medium, provided the orCellular automata (CA) methods have been widely ap-
plied to model brain tumor growth [1,2]. Although CA
models are good at describing cell-cell and cell-
microenvironment interactions, this type of discrete
modelling approach falls short on investigating most
fluid dynamic aspects of the tumor microenvironment.
Alternatively, Continuum models employ systems of par-
tial differential equations to simulate the solid tumor in-
vasion by updating boundaries of different sub-domains
of tumor based on the level-set method [3,4]. It is, how-
ever, hard with this approach to describe cell-cell inter-
actions, such as the competition among cells for
nutrients. In general neither continuum nor discrete
models can accurately simulate cancer spatio-temporal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hybrid discrete-continuum (HDC) model that couples
a cellular automaton module with a continuum mod-
ule was proposed by Anderson and co-workers [5,6].
Although these models have not considered the
effects of any gene-protein signaling pathways such as
the EGFR pathway, computational cancer biologists
have already studied them extensively. Recent studies
showed that EGFR pathway plays an important role
in the evolution of brain cancer [7-9]. Therefore, the
existing multi-scale agent-based tumor models incor-
porated an EGFR signaling pathway [10,11] at the
molecular scale to enable individual cells to choose
their phenotypic trait between proliferation and migra-
tion based on the pathway's state [10,12,13]. As indi-
cated by Hanahan and Weinberg[14], angiogenesis is
a significant transforming phase in tumor growth.
During the angiogenesis phase, tumor cells secret vas-
cular endothelial growth factors (VEGF) [15,16] into
the microenvironment to induce and sustain new ca-
pillary sprouts migrating from pre-existing vasculature
towards the tumor. This in turn helps to maintain
tumor cells’ metabolism by supplying them with glu-
cose and oxygen and subsequently leads to metastasis.
However, our previous agent-based models [10-13,17]
did not explicitly take tumor-induced angiogenesis
into consideration.
In this paper, we presented a novel multi-scale agent-
based model to describe tumor growth with angiogen-
esis and study the response of brain cancer to EGFR
tyrosine kinase inhibitors (TKIs) [18]. Several rates of
changes of molecular species, such as PLCγ, CDh1 and
cycCDK will determine a tumor cell’s phenotypic
switch.
In order to integrate an angiogenesis module into the
existing agent-based tumor growth models [10,11,13,17],
we developed a set of rules that underline the migra-
tion of endothelial cells and the branching of vessel
sprouts. Compared to previous developed HDC rules
[19], these rules which directly defined the probabil-
ities of migration of endothelia cells are more suitable
for implementation into an agent-based model. The
tumor growth and angiogenesis are coupled through
VEGF secreted by the tumor cells and through the
glucose and oxygen permeated from the neo-vascula-
ture. As the neo-vasculature develops, glucose and
oxygen penetrate from the blood vessels and diffuse
throughout the tumor microenvironment to promote
further tumor growth, which in turn influences the
concentration of VEGF.
The simulation results demonstrate that we can inves-
tigate the response of brain cancer to tyrosine kinase
inhibitors (TKIs) and also can use the model to reveal
the dual role of angiogenesis.Implementation
Our model encompasses four biological scales (Figure 1):
the molecular scale, the cellular scale, the micro-
environmental scale and the tissue scale. The molecular
scale consists of the EGFR signaling and cell cycle path-
ways (Figure 2). The cellular scale describes the pheno-
typic switch of the tumor cells which is determined by
the molecular scale, the cell-cell and the cell-
microenvironment interactions (Figure 3). The micro-
environmental scale provides a connection between the
micro-vasculature (angiogenesis) and the tumor cells.
Tumor cells consume glucose and oxygen nutrients.
Transforming growth factor alpha (TGFα) secreted by
tumor cells triggers the EGFR signaling pathway, which
in turn determines cell’s phenotypic switch. Oxygen
plays an important role in the cell cycle during the pro-
liferation phase. The VEGF secreted by the tumor cells
induces angiogenesis. Meanwhile, TGFα, glucose, oxygen
and VEGF diffuse continuously in the tumor microenvir-
onment. The tissue scale focuses on angiogenesis
(Figure 4). Blood vessel sprouts migrate and branch via
tip endothelial cells' migration in response to VEGF
chemotaxis and fibronectin haptotaxis. The new blood
vessels supply tumor cells with glucose and oxygen to
maintain their metabolism and further invasion.
We performed our simulations on a two-dimensional
square lattice. The lattice size was set to L = 200 repre-
senting a 4 ~ 5 mm length of a brain tissue slice. The lat-
tice spacing is 20 μm, which is approximately the
diameter of tumor cells. Initially a parent blood vessel
along with 6 tip endothelial cells is located near the left
boundary of the computational domain. Also a small
cluster of active tumor cells were randomly distributed
as shown in Figure 4. Each tumor cell is initialized with
its age being between 0 ~ 24 hours randomly. The time
step of the simulation is one hour. The details of the
model parameters are in the Additional files 1, 2, 3, 4,
and 5 of this paper.
Molecular scale: signaling pathway
The concentration of each component (Figure 2) in the
EGFR signaling [11,20] and cell-cycle pathways [21] are
described by a system of coupled ordinary differential






where v+ represents the production rate of Xi and v_ the
consumption rate. The parameters of ODEs are in
Additional files 1, 2, 3, and 4. Parameter sensitivity and
model robustness analysis are presented in the results
section. These methods enabled us to determine which
parameters of the system are more sensitive as well as to
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Figure 1 Flow chart of multi-scale agent-based cancer modeling. The model encompasses four biological scales: the molecular scale,
the cellular scale, the micro-environmental scale and the tissue scale. The molecular scale consists of the EGFR signaling and cell cycle
pathways (Figure 2). The cellular scale simulates the phenotypic switch of the tumor cells as determined by the molecular scale, the
cell-cell and the cell-microenvironment interactions (Figure 3). The micro-environmental scale provides a connection between the
micro-vasculature (angiogenesis) and the tumor cells. Tumor cells consume glucose and oxygen nutrients. The tumor growth factor
alpha (TGFα) secreted by tumor cells triggers the EGFR signaling pathway, which in turn determines cell’s phenotype switch. Oxygen
plays an important role in the cell cycle during the proliferation phase. The VEGF secreted by the tumor cells induces angiogenesis.
The tissue scale focuses on angiogenesis (Figure 4). Blood vessel sprouts migrate and branch via tip endothelial cells' migration in
response to VEGF chemotaxis and fibronectin haptotaxis.
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ameter perturbations.
Cellular scale: phenotype switch of tumor cells
as "agents"
At every simulation step, each "agent" (i.e. a brain tu-
mor cell) switches its phenotype according to the
following rules:
1. First, each agent evaluates the concentration of
glucose at its current location. If the concentration
is greater than the cell active threshold, the
agent becomes active and uses its EGFR signaling
pathway to determine its phenotype. If the
concentration of glucose is less than the dead
threshold, the cell dies. If the concentration is
between active and dead thresholds, the
agent enters into a reversible quiescent
state [10].2. Each active agent evaluates its migration potential
(MP) by the following equation:
MP PLCγ½  ¼ d PLCγ½ =dt; ð2Þ
where d[PLCγ]/dt is the rate of change of the PLCγ
concentration. If MP is greater than a threshold
σPLCγ, the average rate of change of PLCγ
concentration, the agent will choose the migration
phenotype.
3. If MP is less than σPLCγ, the agent starts to
proliferate. If the concentration of CDh1 is less than
a threshold thr1 and the concentration of cycCDk is
greater than the threshold thr2, the cell divides. After
that, the cell chooses the most attractive free site
(detailed in equation (3)) in the neighborhood to
deliver its offspring. If there is no empty
neighborhood, the cell turns into a reversible
quiescent state until free space becomes
available.
Figure 2 EGFR signaling pathway connected to cell cycle pathway with TKIs to block the EGFR signaling pathway. EGFR signaling
pathway is connected to the cell cycle pathway, and TKIs block the EGFR signaling pathway.
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mentioned above according to the following
probability:
Pj ¼ ψGj=Fj þ 1 ψð Þεj; ð3Þ
where Gj is the glucose concentration at location j, Fj
is the fibronectin concentration at j, εj ~N(0,1) is a
normally distributed error term, the parameter ψ
2(0, 1) represents the extent of the search precision,
which is set to 0.7 [22].
Microenvironmental scale: extracellular chemotaxis
Five extracellular micro-environmental factors, glucose,
oxygen, TGFα, VEGF and fibronectin are included in this
model. A set of reaction–diffusion equations describe
the diffusion, penetration and uptake of glucose, oxygen
and VEGF.
Glucose first penetrates blood vessels, and then dif-
fuses in the extracellular microenvironment. After that,
it is consumed by the tumor cells. This process is mod-
eled by the following equation:
@G
@t
¼ DGΔG þ Xves t; xð ÞqG Gblood  G
 
 Xtum t; xð ÞUG; ð4Þ
where G is the glucose concentration, Δ  r2 is the
Laplace operator, DG is the diffusivity of glucose. qG= 2
πrpG, where pG is the vessel permeability for glucose and
r is the blood vessels' average radius. In addition, Gbloodis the glucose concentration in blood and UG is the cell’s
glucose uptake rate. The time dependent characteristic
function Xves (t,x) is equal to 1, if a blood vessel is
present at x; otherwise it is equal to 0. Xtum (t,x) is equal
to 1 in the tumor region and is equal to 0 elsewhere. Xves
and Xtum are updated at each simulation step according
to the developing profile of the tumor and its micro-
vascularity.
Oxygen also permeates the blood vessels' walls,
diffuses in the surrounding and is consumed by




¼ DCΔC þ Xves t; xð ÞqC Cblood  C
 
 Xtum t; xð ÞUC ; ð5Þ
where C is the oxygen concentration, DC is the
oxygen diffusivity, qC is the vessel permeability for
oxygen, and UC is a cell’s uptake rate of oxygen.
TGFα, an analogue of EGF, is secreted by tumor cells
and can be paracrine and juxtacrine [23]. Equation (6)
describes the diffusion and secretion of TGFα.
@T
@t
¼ DTΔT  Xves t; xð ÞqTT þ Xtum t; xð ÞST
 δTT ; ð6Þ
where T is the TGFα concentration, DT is its diffusivity,
qT is vessel permeability to TGFα. ST is a cell’s net
Figure 3 Illustrations of phenotype switch "decision" of tumor cell. Please see details in the main text (Cellular scale: Phenotype switch of
tumor cell as "agent").
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of TGFα.
We applied homogeneous Neumann boundary con-
ditions for all the above equations by assuming zero
flux along the boundary of the considered domain.
Additional file 5: Table A5 and Additional file 6:
Equations A1–A5 list the parameters and initial con-
ditions of the equations. We solved these equations
numerically with the finite difference method [24].Tissue scale: angiogenesis
Tumor induced angiogenesis is due to the secretion of
VEGF by the tumor cells. VEGF diffuses into thesurrounding corneal tissue and is also consumed by the




¼ DVΔV  Xves t; xð ÞqVV þ Xtum t; xð ÞSV
 δVV ; ð7Þ
where V is the VEGF concentration, DV is the diffusivity
of VEGF, qV is the vessel permeability for VEGF and SV
is a cell’s VEGF secretion rate. δV is the natural decay
rate of VEGF.
Fibronectin is a component of the corneal tissue
secreted by endothelial cells. In addition, tumor cells can
Figure 4 Probability of migration of tip endothelial cell. The tip
endothelial cell probabilistically moves up, down, right, or left, or
stays at its current position.
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¼ Xves t; xð Þβ Xtum t; xð ÞγF ; ð8Þ
where F is the fibronectin concentration, β and γ are
positive constants representing the production and up-
take rates, respectively.
We assume that the motion of individual endothelial
cell (EC) located at the tip of a capillary sprout governs
the motion of the whole sprout. Chemotaxis in response
to VEGF gradients and haptotaxis in response to fibro-
nectin are the major factors that influence the motion of
the endothelial cells at the capillary sprout tip [25].
We defined the probability of migration of a tip endo-
thelial cell (see Figure 4) as
Pk / α kvkv þ V rV þ λrF
 
:lk ;⋯⋯k
¼ 1; 2; 3; 4; ð9Þ
where V is the VEGF concentration, F is fibronection
concentration and lk is the directional vector along
the kth direction. The term αkv= kv þ Vð Þ rV models
chemotaxis in response to VEGF gradients [19], where α
is the chemotactic coefficient and kv is a positive con-
stant controlling the weight of VEGF concentration in
chemotactic sensitivity. The term λrF models thehaptotatic influence of fibronectin on the endothelial
cells, where λ is the haptotatic coefficient.
For a given tip of endothelial cells at location (i, j), the
un-normalized migration probabilities can be calculated
from equation (9) as follows:
P1 ¼ αkV= kV þ V i; jð Þð Þ V i; jþ 1ð Þ  V i; jð Þð Þ
þ λ F i; jþ 1ð Þ  F i; jð Þð Þ;
P2 ¼ αkV= kV þ V i; jð Þð Þ V i; j 1ð Þ  V i; jð Þð Þ
þλ F i; j 1ð Þ  F i; jð Þð Þ;
P3 ¼ αkV= kV þ V i; jð Þð Þ V iþ 1; jð Þ  V i; jð Þð Þ
þλ F iþ 1; jð Þ  F i; jð Þð Þ;
P4 ¼ αkV= kV þ V i; jð Þð Þ V i 1; jð Þ  V i; jð Þð Þ
þλ F i 1; jð Þ  F i; jð Þð Þ: ð10Þ
The un-normalized probability P5, for a tip cell to re-
main stationary is the average of P1, P2, P3 and P4. After
normalization, the above equations give the likelihood of
the tip endothelial cell to move up, down, right, or left,
or stay at its current position. The probability, P5, for a
tip cell to remain stationary is the average of P1, P2, P3
and P4.
The algorithm related to angiogenesis is as follows:
1. Calculate the migration probabilities of ECs:1.1 Solve the equations (7) and (8), and then calculate
P1-P5 from (10);
1.2 Normalize the above numbers: P˜ i ¼
Pi=
P5
j¼1Pj; :i ¼ 1; 2; . . . ; 5; define intervals I1 ¼








j; i ¼ 2; . . . ; 5.
2. For every sprout tip cell, we check whether the age
of vessel is greater than 18 hours and whether there
are any free sites in its nearest neighborhood.
2.1 Sprout branching: If the above conditions are
satisfied, two random numbers r1 and r2 between
0 and 1 are generated. If r1 2 I2 and r2 2 I3, then
we move two endothelial cells one below and one
to the right of the spout tip endothelial cell.
2.2. Sprout migrating: If the above branching
conditions are not satisfied, we generate another
random number r between 0 and 1. If r 2 I3, we
move the tip endothelial cell to the right of spout
tip endothelial cell.
3. Anastomosis: If two sprouts encounter each other, a
new sprout continues to grow.
TKI treatment
This study uses TKIs, particularly gefitinib, as inhibitors
delivered by capillary vessels to treat brain cancer. The
TKIs are modeled as a continuous concentration field.
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http://www.biomedcentral.com/1471-2105/13/218These molecules permeate the blood vessels and diffuse
continuously in the microenvironment to produce an ac-
cumulative inhibitive effect on the tumor growth. We





þ Xves t; xð ÞqTki Tkiblood  Tki
 
 Xtum t; xð ÞUTki  δTkiTki; ð11Þ
where DTKi is the diffusivity of the TKIs, qTKi is the ves-
sel permeability for TKIs, TKi blood is the blood TKIs
concentration, UTKi is a cell’s uptake rate of TKIs, and
δTki is the natural decay rate of TKIs.
The EGFR signaling pathway controls a cell’s pheno-
typic switch by binding TGFα molecules to the EGF
receptors. Because the TKI molecules inhibit the autop-
hosphorylation receptors, the downstream EGFR path-
way responsible for a cell's phenotypic switch remains
inactivated [26]. The binding and unbinding processes of
TKIs to EGFR with constant rates kb and ku, respectively,




EGFR : TKI ð12Þ
Since the chemical reaction rate is much faster than
the cells' phenotypic switch [26], the concentration of
EGFR: TKI complex in equation (12) can be obtained by
applying Michaelis–Menten kinetics as follows:
EGFR : TKI½  ¼ EGFR½ 0 TKI½ 
km þ TKI½  ð13Þ
where km is the Michaelis constant, km  kb / ku, and
[EGFR]0 is the initial concentration of the EGFR. We
can then derive the effective amount of EGFR for the ac-
tivation of downstream factors as follows:
EGFR½ eff ¼ EGFR½ 0  EGFR : TKI½  ð14Þ
Because of the TKI treatment, the effective amount of
EGFR of some tumor cells will decrease. The decrease of
the amount of effective EGFR results in a slow rate of
change of PLCγ concentration. This in turn inhibits
tumor progression by reducing the migration potential
of these tumor cells (see equation 2 and detailed pheno-
type change of tumor cells in Figure 3).
Finally, we summarize our computing algorithm at
each step across multi-scales (Figure 1) as follows. At
micro-environmental scale, we solve the PDEs (equa-
tions 4–6) to obtain the spatial concentration distribu-
tions of glucose, oxygen and TGFα. At molecular scale,
we use the calculated local TGFα concentration as the
input for EGFR signaling pathway (equation 1) for each
tumor cell. At cellular scale, tumor cells' migrationpotential (MP) (equation 2) is computed to determine
their phenotypic switch (migration or proliferation);
meanwhile, other phenotypic switches (quiescent or
apoptosis) are associated with the current value of
oxygen and glucose. At tissue scale, the spatial con-
centration distributions of VEGF and fibronectin
(equations 7–8) will guide the tip endothelial cells' mi-
gration and sprout branching. In turn, the remodeled
vasculature at tissue scale influences the spatial con-
centration distributions of glucose, oxygen and TGFα
at micro-environmental scale. For TKI treatment, the
TKI distribution is integrated into molecular scale by
solving equation 11 along with aforementioned equa-
tions 4–6, and the initial value of EGFR is varied by
equations 12–14 as well.
Results
We have implemented the above model into software
"ABM-TKI" in the Matlab programming environment.
“ABM-TKI” is a tool employing agent-based model
(ABM) to simulate brain tumor growth. It includes
an EGFR signaling pathway, a related cell-cycle,
angiogenesis and TKIs treatment. We can employ
this tool to predict the responses of brain cancer
and reveal the dual roles of angiogenesis under TKI
treatment.
Regarding software usage, the user can download and
decompress the package from the project home page
(https://sites.google.com/site/agentbasedtumormodeling/
home). Then the user can run the program in Matlab
(version R2007b or higher) with input as: angiog_tumor
(time,isdrug).The input "time" is the period from the be-
ginning of the simulation to the end. The "isdrug = 1"
means TKI treatment and "isdrug = 0" means no TKI
treatment. For example: "angiog_tumor(150,0)" will give
the tumor growth profile without TKI treatment from
0 hour to 150 hours; "angiog_tumor(300,1)" will give the
tumor growth profile with TKI treatment from 0 hour to
300 hours.
The output includes: (a) the vascular tumor growth
pattern with or without TKI treatment; (b) the tumor
growth visualization with the background of fibronectin;
(c) the spatio-temporal evolution of the concentration of
glucose, oxygen, TGFα and/or TKI; (d) various tumor
cell numbers such as active cells, apoptotic cells, migra-
tory cells, proliferative cells, quiescent cells and the
number of endothelial cells; (e) the average change rate
of PLCγ with or without TKI treatment.
Vascular tumor growth patterns
The vascularized tumor patterns at 60, 90, 120 and
150 hours are shown in Figure 5a, where different colors
denote various tumor cell states: active (blue), quiescent









Figure 5 Simulation of vascular tumor growth without TKI treatment. (a) The evolution of vascular tumor patterns at 60, 90, 120 and 150
hours. (b) The distribution of glucose, oxygen, TGFα and VEGF in microenvironment at 150 hours. (c) Different types of cell numbers from 0 hour
to 150 hours. (d) Proliferation rate of tumor cells derived from simulations (red line) and from in vitro experimental observations (blue line) for
t=0-96 hours.
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Figure A1 for more details). The active tumor cells are
comprised of migratory cells, cells that have just com-
pleted their proliferation process, and cells that just
switched back from quiescent state to the active state.
Additional file 8: Figure A2 shows the growth of the
tumor microvascularity and the fibronectin concentra-
tion at different time interval. Figure 5a showed that
those tumor cells tend to migrate to locations near the
vessels, where the glucose concentration level is the
highest. Around t = 60 hours, the tumor was comprised
of active cells and some quiescent cells. Around
t = 90 hours some dead cells appeared in the tumor
mass. From t = 120 hours to t = 150 hours, the number
of both dead and active cells kept increasing. At
t = 150 hours, we found that some quiescent cells near
blood vessels switched back to active cells. At this time,
the tumor developed a tree branching microvasculature,
which is much denser near the tumor. Figure 5b shows
the distributions of different micro-environmental fac-
tors (glucose, TGFα, oxygen, VEGF) at t = 150 hours.
Given the space limitation, we show the results at a
single time interval. The concentrations of these mole-
cules at different times are shown in the Additional file 9:
Figure A3, with different colors representing different
levels of concentration. We found that the descendingorder of the diffusion rate for the four molecular species is
as follows: oxygen, glucose, VEGF or TGFα.
Figure 5c shows the numbers of different types
of cells as a function of time. The number of active
cells increased monotonically with time. The number
of apoptotic cells increased abruptly at around
t = 60 hours and kept increasing until the tumor micro-
vasculature developed at t = 150 hours. The number of
quiescent tumor cells kept increasing from t = 0 to
130 hours, and then began to decrease. The number of
endothelial cells increased rapidly during the whole
simulation time. The detailed evolutions of the numbers
of various cells are shown in Additional file 10: Figure
A4 separately.
In Figure 5d, we present the proliferation rate of
tumor cells as a function of time from our simulation
and from in vitro experimental results (at t = 96 hours)
[27]. The in vitro experimental data are from human gli-
oma tumor-initiating cells derived from 7 patients (GBM
1–7). The plotted experimental data are the mean and
standard deviation values from the seven cell lines. We
took the mean value of these data as the blue line in
Figure 5d. The mean squared error of our prediction is
0.1421. The simulation and experimental data in
Figure 5d are in very good agreement, which is an im-
portant validation of our model.
Figure 6 Simulation of vascular tumor growth with TKI treatment. (a) Vascular tumor growth patterns with TKI treatment at 60, 150, 240 and
300 hours; (b) The distribution of TKI in tumor vasculature at 300 hours; (c) Average change rate of PLCγ from hour 0 to 300 hours.
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In our study we chose gefitinib as the EGFR TKI to treat
brain cancer. In this section the term TKI refers to treat-
ing cell by gefitinib. Figure 6a shows the simulation pro-
files of the vascularized tumor growth with TKI
treatment from t = 0 to 300 hours. The different colors
represent cell types as defined in Figure 5a. The results
in Figure 6a show that the tumor expansion slowed
down obviously by the TKI treatment. Additional files
11-12: Figure A5-6 show the detailed vascular tumor
growth profile with TKI treatment as well as that in the
presence of fibronectin at different time intervals.
Figure 6b shows the distribution profile of TKIs con-
centration at t = 300 hours which is similar to the struc-
ture of tumor microvasculature. The Additional file 13:
Figure A7 and Additional file 14: Figure A8 demonstrate
the evolution of distributions of glucose, oxygen, TGFα
and VEGF as well as TKIs during the treatment at differ-
ent time intervals.
Figure 6c shows the average rate of change of PLCγ as
a function of time. The PLCγ average rate of changeincreases from t = 0 to 60 hours and then it starts de-
creasing with an exception at around t = 75 hours where
the data show a hump. Finally, the curve goes down
after t = 125 hours. Since Additional file 10: Figure A4
shows the average rate of change of PLCγ always
increases without TKI treatment, TKI treatment greatly
affects the average rate of change of PLCγ. The numbers
of various cells with TKI treatment are shown in
Additional file 15: Figure A9.
Figure 7a shows the cell survival rate under TKI
treatment from t = 0 to 300 hours which decreased
until t = 150 hours and then increased again until
t = 300 hours.
Figure 7b demonstrates that the simulated cell survival
rate has a trend similar with experimental results. The
purple line in the figure represents the average from a
hundred simulations. Human glioma tumor-initiating
cells are derived from 7 patients (GBM 1–7) [27] for
in vitro experiments observed for 96 hours, these experi-
mental data are shown by the multiple lines in the
figure. In the experiment human glioma tumor growth
a b
Figure 7 Prediction and validation of cell survival percentage during TKI treatment. (a) Prediction of cell survival percentage during TKI
treatment from 0 hour to 300 hours; (b) Cell survival percentage from simulations (purple line) and from in vitro experimental observations
(black line) for t=0-96 hours.
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tion of 1 μM, while in our simulation we also chose gefi-
tinib as TKI and its concentration near tumor region is
also close to 1 μM from t = 0 to 100 hours. The relatively
good agreement between the simulation prediction and
the experimental results constitutes an important valid-
ation of our model.
Sensitivity analysis and model robustness
Parameter sensitivity analysis is to quantitatively dis-
cover sensitive parameters in the system. And robust-
ness analysis is to examine whether the system is stable
to modest fluctuations of these sensitive parameter
values.
In this work, local parameter sensitivity analysis [28-30]
was employed to understand the relationship between the
migration potential (defined above) of tumor cell and the
variations in individual parameter values. The sensitivityFigure 8 Sensitivity analysis of EGFR signaling pathway. The result sho
to the initial concentration of EGFR (X2) and TGFα (X1). The result also show








where P is the parameter that is varied and MP is
tumor cell's migration potential; ΔMP is the corre-
sponding change in MP due to a small change in P
denoted by ΔP. Each individual parameter is increased
(or decreased) by 10% from its original value, and the
resulting percentage change of the migration potential
is computed. Figure 8 shows that the migration po-
tential of the cells is most sensitive to the initial
concentration of EGFR (X2) and TGFα (X1). The sen-
sitivity analysis also demonstrates that kinetic rates,
k1, k2, k3, k5, K4 and V4, are more critical than others
in the system. Furthermore, it turns out that the
developed intracellular pathway system is ratherws that the migration potential of brain cancer cells is most sensitive
s us forward kinetic rates (k1, k2, k3, k5) are more important in the
s robust.
Figure 9 Model robustness analysis. TGFα (X1), EGFR (X2), PLCγ (X6), and k1, k2, k3, k5, K4 and V4 were varied their values by 0.1-fold, 2.0 fold, 5.0
fold, 10.0 fold, 50.0-fold, and 100.0-fold of original reference values each time. The results show that the absolute values of the robustness
indexes are less than 0.1894 with respect to most parameters (except TGFα and k1) for variations between 0.1-fold and 10.0-fold.
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than 1.8%.
Based on above sensitivity analysis results, we selected
3 pathway components, TGFα (X1), EGFR (X2) and PLCγ
(X6), and 6 kinetic rates including k1, k2, k3, k5, K4 and V4
as key parameters to investigate the robustness of the
model to much larger ranges of parameter variations. For
each of these parameters, we varied its value by 0.1-fold,
2.0 fold, 5.0 fold, 10.0 fold, 50.0-fold, and 100.0-fold of its
original reference value respectively. Each time, only one
of the above parameters was varied with a corresponding
fold change, and all other parameters were kept fixed.
We chose active cell number (ACN) at 100 hours in each
simulation as the system outcome, and examined the sys-
tem responses to the above parameter variations. We
defined the robustness index (R) as follows:
R ¼ ACNp ACN0
ACN0
; ð16Þwhere ACNp is the active cell number with the varied
parameter p, and ACN0 is the average active cell number
from the 100 simulations with unvaried reference
parameters.
Figure 9 shows that for variations between 0.1-fold
and 10.0-fold, the absolute values of the robustness
index is less than 0.1894 with respect to most para-
meters (except TGFα and k1). Figure 10 shows the
detailed analyses of the system robustness with respect
to TGFα and k1 at variations between 5.0-fold to 10.0-
fold. The results show that regarding TGFα and k1, at
the variations between 0.1-fold and 7.0-fold, the absolute
values of the robustness indexes are less than 0.1894.
Furthermore, for some parameters, such as PLCγ, k2, k3,
k5, K4, the robustness index is very small even with the
variations up to 100.0-fold. Then we calculated the coef-
ficient of variation (CV) of system outcomes which is
defined as the ratio of the standard deviation to the
mean of the above variational active cell numbers. At
Figure 10 Detailed robustness analyses for TGFα and k1. TGFα (X1), and k1 were varied by 5.0-fold, 6.0 fold, 7.0 fold, 8.0 fold, 9.0-fold, and
10.0-fold of original reference values each time. The results show the absolute values of the robustness indexes are less than 0.1894 with respect
to TGFα and k1 for variations between 0.1-fold and 7.0-fold.
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the CV of system outcomes is 0.2007 which is much less
than 1, indicating that the system is relatively stable to
the parameter variations. These results reveal that our
model is comparably robust with respect to relatively
large ranges of parameter variations.Discussion
We developed a multi-scale model by integrating a novel
angiogenesis module into an agent-based tumor model
based on a set of reaction–diffusion equations that de-
scribe the spatio-temporal evolution of the distributions
of micro-environmental factors such as glucose, oxygen,
TGFα, VEGF and fibronectin. These molecular species
regulate tumor growth during angiogenesis. Each tumor
cell is equipped with an EGFR signaling pathway linked
to a cell-cycle to determine its phenotype.
Our simulations show several interesting findings. The
first is that tumor cells tend to move towards blood ves-
sels and gradually developed to a fan-shape as shown in
Figure 5a. We interpret this result as follows. Since the
nutrients (glucose and oxygen) concentrations are higher
at locations near the blood vessels, they attract tumor
cells.
The second interesting finding is that blood vessels
tend to migrate to tumor and form a dense tree-
branching vascular network. The reason is that a high
VEGF gradient close to the tumor attracts endothelial
cells, which in turn lead to branching of vessels in these
regions.
The third interesting finding is that TKI treatment can
inhibit tumor progression. The binding of TKI mole-
cules to EGFR decreases the amount of effective EGFR,
which results in low expression of PLCγ and low cell’s
migration potential (Figure 6c). As a result, tumor inva-
sion slows down.The fourth interesting result is that the tumor cells'
survival rate does not always decrease. This is due to the
dual role of angiogenesis. Newly formed capillaries deli-
vers a substantial amount of TKI molecules to tumor
cells and blocks the EGFR signaling pathway, which lead
to an inhibition of tumor growth. This in turn results in
a decreased cell survival rate in the early stage of the
tumor development. On the other hand, new capillaries
transported a lot of glucose and oxygen to tumor cells
which results in an increased cell survival rate at later
stages (Figure 7a). The implications of the dual roles of
angiogenesis reveal that clinical personnel should de-
crease cancer progression by using TKI treatment and
inhibiting tumor-induced angiogenesis at the same time.
The sensitivity analysis reveals sensitive parameters in
the EGFR signaling pathway. The robustness study con-
firms that our model is relatively robust and stable to
fluctuations of these sensitive parameters.
Herein we used the two-dimensional in vitro experi-
ments [27] to validate the effectiveness of the model.
These experiments employed two-dimensional experi-
mental protocol to isolate and plate human glioma
tumor-initiating cells in Martrigel-coated culture flasks.
Figure 5d and Figure 7b demonstrate that our in silico
model does have strong predictive power and great po-
tential for clinical work.
We are going to extend the model to three dimen-
sions to simulate in vivo tumor growth for real clinical
purposes. A three-dimensional lattice is indispensable
for the simulation of in vivo tumor growth with angio-
genesis, because tumor cells' activities, vasculature
structure, and chemical cues' diffusion in three-
dimensional heterogeneous tumor growth environment
are very different from two-dimensional. Moreover,
three-dimensional simulations require parallel comput-
ing techniques [32] to relieve the heavy computing
request.
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corporating more realistic biological and physical fea-
tures, such as blood flow and tumor growth-induced
pressure [33] in the future.
Conclusions
This work presents a novel multi-scale agent-based brain
tumor model encompassing an EGFR signaling pathway
together with a related cell-cycle, an angiogenesis mod-
ule and TKI treatment. It incorporates four relevant bio-
logical scales: the molecular scale, the cellular scale, the
microenvironment scale and the tissue scale. At the mo-
lecular scale, a system of ordinary differential equations
simulates the dynamics of the EGFR signaling pathway
and the cell cycle to determine the cells' phenotypic
switch at the cellular scale. We employed a set of partial
differential equations to simulate the concentration
changes of five extracellular chemical cues (glucose, oxy-
gen, TGFα, VEGF and fibronectin) in the tumor micro-
environmental scale. Angiogenesis was coupled into
tumor growth through VEGF secreted by the tumor cells
and through the glucose and oxygen permeated from
the neo-vasculature at the tissue scale. Moreover, we
integrated TKI treatment into EGFR signaling pathway
to block the activation of EGFR.
Our simulations demonstrate that the entire tumor
growth profile is a collective behaviour of its cells regu-
lated by the EGFR signaling pathway and the cell cycle.
We also discovered that angiogenesis has dual effects on
TKI treatment: on one hand, neo-vasculature can deliver
TKIs to decrease the tumor invasion, whereas on the
other hand, it can transport a lot of nutrients ( glucose
and oxygen) to tumor cells to maintain their metabol-
ism, which results in an increase of cell survival rate at
late simulation stage. There is a great similarity between
the simulation results and existing in vitro experimental
data. Further analyses show that our model has strong
robustness regarding to the relatively large changes of
the sensitive model parameters.
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